Skip to main content

Table 3 Univariate and multivariate analyses for progression-free survival using a Cox proportional hazards model

From: Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment

Variables

PFS

Univariate

Multivariate

Hazard ratio*

P

Hazard ratio*

P

Age (years)

    

  ≤ 60

1.00

   

  > 60

1.07 (0.83–1.38)

0.613

  

BMI (kg/m2)

    

  ≤ 23.9

1.00

 

1.00

 

  > 23.9

0.72 (0.55–0.94)

0.015

0.83 (0.63–1.09)

0.184

Gender

    

 Male

1.00

   

 Female

1.02 (0.75–1.39)

0.903

  

ASA score

    

 1

1.00

   

 2

1.23 (0.76–2.00)

0.402

  

 3

1.39 (0.79–2.46)

0.255

  

ECOG (per 1 increase)

1.61 (1.32–1.96)

 < 0.001

1.27 (1.01–1.60)

0.043

Comorbidities

    

 No

1.00

   

 Yes

1.13 (0.87–1.48)

0.363

  

Location

    

 Localized

1.00

0.383

  

 Diffused

3.81 (2.44–5.94)

 < 0.001

  

Location

    

 Upper

1.00

 

1.00

 

 Middle

1.10 (0.73–1.66)

0.633

1.44 (0.93–2.23)

0.100

 Lower

0.94 (0.70–1.27)

0.686

1.25 (0.90–1.72)

0.181

 Diffused

3.74 (2.31–6.08)

 < 0.001

1.77 (1.02–3.08)

0.044

Diameter (cm)

    

  ≤ 2

1.00

 

1.00

 

 2–5

1.96 (1.47–2.62)

 < 0.001

1.15 (0.85–1.55)

0.364

  > 5

4.30 (2.99–6.17)

 < 0.001

1.92 (1.26–2.95)

0.003

Differentiation

    

 Well-moderate

1.00

 

1.00

 

 Poor

1.32 (0.98–1.77)

0.064

1.03 (0.77–1.39)

0.833

Lymphovascular invasion

    

 No

1.00

   

 Yes

2.94 (2.27–3.81)

 < 0.001

  

ypT

    

 T0

1.00

   

 T1

1.68 (0.57–4.93)

0.342

  

 T2

2.11 (0.79–5.64)

0.138

  

 T3

3.94 (1.56–9.94)

0.004

  

 T4

7.04 (2.89–17.16)

 < 0.001

  

ypN

    

 N0

1.00

   

 N1

1.95 (1.30–2.93)

0.001

  

 N2

3.01 (2.02–4.47)

 < 0.001

  

 N3

7.46 (5.28–10.53)

 < 0.001

  

ypTNM stage

    

 0

1.00

1.00

1.00

 

 I

0.94 (0.33–2.63)

0.901

0.92 (0.33–2.61)

0.880

 II

2.36 (0.94–5.95)

0.067

1.98 (0.782–5.02)

0.150

 III

7.76 (3.19–18.91)

 < 0.001

5.32 (2.15–13.20)

 < 0.001

Resection type

    

 Subtotal

1.00

   

 Total

1.76 (1.36–2.28)

 < 0.001

  

Adjuvant chemotherapy

    

 Yes

1.00

 

1.00

 

 No

1.58 (1.16–2.15)

0.003

1.42 (1.03–1.96)

0.034

Cycle of NACT

    

  > 3

1.00

   

  ≤ 3

1.39 (0.85–2.28)

0.192

  

Clavien–Dindo

    

 Grade 0–II

1.00

 

1.00

 

 Grade III–IV

1.36 (0.97–1.91)

0.073

1.03 (0.71–1.47)

0.889

CEA

    

  ≤ 5.72

1.00

   

  > 5.72

2.30 (1.70–3.11)

 < 0.001

  

CA199

    

  ≤ 15.00

1.00

   

  > 15.00

1.71 (1.32–2.21)

 < 0.001

  

CA724

    

  ≤ 2.60

1.00

   

  > 2.60

1.81 (1.38–2.38)

 < 0.001

  

Post-NACT CTM

    

 0

1.00

 

1.00

 

 1

1.54 (1.06–2.23)

0.022

1.37 (0.94–2.00)

0.099

 2

2.77 (1.87–4.10)

 < 0.001

2.07 (1.37–3.10)

 < 0.001

 3

4.54 (2.85–7.22)

 < 0.001

3.11 (1.91–5.07)

 < 0.001

  1. Values in parentheses are *95 percent confidence intervals. ASA, American Society of Anesthesiologists; BMI, Body Mass Index; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4; CEA, carcinoembryonic antigen; CTM, combination of tumor markers; ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; PFS, progression-free survival; NACT, neoadjuvant chemotherapy; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4;